التحقيق في الهدف الميكانيكي للرابامايسين والمسارات المماثلة في أمراض القلب والأوعية الدموية لزيادة وظائف القلب

Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005; 352(16):1685-1695. DOI: https://doi.org/10.1056/NEJMra043430

Pawitan J. Molecular pathogenesis of atherosclerosis and implication for therapy. Int. Med. J. Malays. 2010; 9(2):7-14. DOI: https://doi.org/10.31436/imjm.v9i2.712

Walpola P.L., Gotlieb A.I., Cybulsky M.I. and Langille B.L. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress. Arterioscler. Thromb. Vasc. Biol. 1995; 15(1):2-10. DOI: https://doi.org/10.1161/01.ATV.15.1.2

Samson S., Mundkur L. and Kakkar V.V. Immune response to lipoproteins in atherosclerosis. Cholesterol 2012; 2012:571846. DOI: https://doi.org/10.1155/2012/571846

Düvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010; 39(2):171-183. DOI: https://doi.org/10.1016/j.molcel.2010.06.022

Peterson T.R., Sengupta S.S., Harris T.E., Carmack A.E., Kang S.A., Balderas E. et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011; 146(3):408-420. DOI: https://doi.org/10.1016/j.cell.2011.06.034

Brown M.S. and Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89(3):331-340. DOI: https://doi.org/10.1016/S0092-8674(00)80213-5

Pérez-Belmonte L.M., Moreno-Santos I., Cabrera-Bueno F., Sánchez-Espín G., Castellano D., Such M. et al. Expression of sterol regulatory element-binding proteins in epicardial adipose tissue in patients with coronary artery disease and diabetes mellitus: preliminary study. Int. J. Med. Sci. 2017; 14(3):268-274. DOI: https://doi.org/10.7150/ijms.17821

Robinet P., Védie B., Chironi G., Gariépy J., Simon A., Moatti N. et al. Characterization of polymorphic structure of SREBP-2 gene: role in atherosclerosis. Atherosclerosis 2003; 168(2):381-387. DOI: https://doi.org/10.1016/S0021-9150(03)00144-8

Halcox J.P., Schenke W.H., Zalos G., Mincemoyer R., Prasad A., Waclawiw M.A. et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106(6):653-658. DOI: https://doi.org/10.1161/01.CIR.0000025404.78001.D8

Förstermann U. and Sessa W.C. Nitric oxide synthases: regulation and function. Eur. Heart J. 2012; 33(7):829-837. DOI: https://doi.org/10.1093/eurheartj/ehr304

Davies M.G. and Hagen P.O. The vascular endothelium. A new horizon. Ann. Surg. 1993; 218(5):593-609. DOI: https://doi.org/10.1097/00000658-199321850-00003

Yang Z. and Ming X.F. mTOR signalling: the molecular interface connecting metabolic stress, aging and cardiovascular diseases. Obes. Rev. 2012; 13 Suppl 2:58-68. DOI: https://doi.org/10.1111/j.1467-789X.2012.01038.x

Sessa W.C. eNOS at a glance. J. Cell Sci. 2004; 117(Pt 12):2427-2429. DOI: https://doi.org/10.1242/jcs.01165

Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K. et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399(6736):597-601. DOI: https://doi.org/10.1038/21218

Huang P.L. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol. Metab. 2009; 20(6):295-302. DOI: https://doi.org/10.1016/j.tem.2009.03.005

Dimmeler S., Dernbach E., Zeiher A.M. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett. 2000; 477(3):258-262. DOI: https://doi.org/10.1016/S0014-5793(00)01657-4

Michell B.J., Chen Z.P., Tiganis T., Stapleton D., Katsis F., Power D.A. et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J. Biol. Chem. 2001; 276(21):17625-17628. DOI: https://doi.org/10.1074/jbc.C100122200

Davignon J. and Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109(23 Suppl 1):III27-III32. DOI: https://doi.org/10.1161/01.CIR.0000131515.03336.f8

Tiefenbacher C.P., Bleeke T., Vahl C., Amann K., Vogt A., Kübler W. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation 2000; 102(18):2172-2179. DOI: https://doi.org/10.1161/01.CIR.102.18.2172

Alp N.J., McAteer M.A., Khoo J., Choudhury R.P., Channon K.M. Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler. Thromb. Vasc. Biol. 2004; 24(3):445-450. DOI: https://doi.org/10.1161/01.ATV.0000115637.48689.77

Peng H., Zhuang Y., Harbeck M.C., He D., Xie L., Chen W. Serine 1179 Phosphorylation of Endothelial Nitric Oxide Synthase Increases Superoxide Generation and Alters Cofactor Regulation. PLoS One 2015; 10(11):e0142854. DOI: https://doi.org/10.1371/journal.pone.0142854

Rajapakse A.G., Yepuri G., Carvas J.M., Stein S., Matter C.M., Scerri I. et al. Hyperactive S6K1 mediates oxidative stress and endothelial dysfunction in aging: inhibition by resveratrol. PLoS One 2011; 6(4):e19237. DOI: https://doi.org/10.1371/journal.pone.0019237

Tarantino G., Capone D. Inhibition of the mTOR pathway: a possible protective role in coronary artery disease. Ann. Med. 2013; 45(4):348-356. DOI: https://doi.org/10.3109/07853890.2013.770333

Marx S.O., Jayaraman T., Go L.O., Marks A.R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res. 1995; 76(3):412-417. DOI: https://doi.org/10.1161/01.RES.76.3.412

Jung C.H., Ro S.H., Cao J., Otto N.M., Kim D.H. mTOR regulation of autophagy. FEBS Lett. 2010; 584(7):1287-1295. DOI: https://doi.org/10.1016/j.febslet.2010.01.017

Naoum J.J., Woodside K.J., Zhang S., Rychahou P.G., Hunter G.C. Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice. Transplant. Proc. 2005; 37(4):1880-1884. DOI: https://doi.org/10.1016/j.transproceed.2005.02.080

Mueller M.A., Beutner F., Teupser D., Ceglarek U., Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis 2008; 198(1):39-48. DOI: https://doi.org/10.1016/j.atherosclerosis.2007.09.019

Nallamothu B.K., Bradley E.H., Krumholz H.M. Time to treatment in primary percutaneous coronary intervention. N. Engl. J. Med. 2007; 357(16):1631-1638. DOI: https://doi.org/10.1056/NEJMra065985

Dazert E., Hall M.N. mTOR signaling in disease. Curr. Opin. Cell Biol. 2011; 23(6):744-755. DOI: https://doi.org/10.1016/j.ceb.2011.09.003

Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011; 12(1):21-35.. DOI: https://doi.org/10.1038/nrm3025

Aoyagi T., Kusakari Y., Xiao C.Y., Inouye B.T., Takahashi M., Scherrer-Crosbie M. Cardiac mTOR protects the heart against ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2012; 303(1):H75-H85. DOI: https://doi.org/10.1152/ajpheart.00241.2012

Hung C.M., Garcia-Haro L., Sparks C.A., Guertin D.A. mTOR-dependent cell survival mechanisms. Cold Spring Harb. Perspect. Biol. 2012; 4(12):a008771. DOI: https://doi.org/10.1101/cshperspect.a008771

Ronnebaum S.M., Patterson C. The FoxO family in cardiac function and dysfunction. Annu. Rev. Physiol. 2010; 72:81-94. DOI: https://doi.org/10.1146/annurev-physiol-021909-135931

Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 2006; 11(6):859-871. DOI: https://doi.org/10.1016/j.devcel.2006.10.007

Pham F.H., Sugden P.H., Clerk A. Regulation of protein kinase B and 4E-BP1 by oxidative stress in cardiac myocytes. Circ. Res. 2000; 86(12):1252-1258. DOI: https://doi.org/10.1161/01.RES.86.12.1252

Pye J., Ardeshirpour F., McCain A., Bellinger D.A., Merricks E., Adams J. Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2003; 284(3):H919-H926. DOI: https://doi.org/10.1152/ajpheart.00851.2002

Wiza C., Nascimento E.B., Ouwens D.M. Role of PRAS40 in Akt and mTOR signaling in health and disease. Am. J. Physiol. Endocrinol. Metab. 2012; 302(12):E1453-E1460. PMID: 22354785. DOI: https://doi.org/10.1152/ajpendo.00660.2011

Völkers M., Toko H., Doroudgar S., Din S., Quijada P., Joyo A.Y. Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1. Proc. Natl. Acad. Sci. U. S. A. 2013; 110(31):12661-12666. DOI: https://doi.org/10.1073/pnas.1301455110

Inoki K., Li Y., Xu T., Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003; 17(15):1829-1834. DOI: https://doi.org/10.1101/gad.1110003

Sciarretta S., Zhai P., Volpe M., Sadoshima J. Pharmacological modulation of autophagy during cardiac stress. J. Cardiovasc. Pharmacol. 2012; 60(3):235-241. DOI: https://doi.org/10.1097/FJC.0b013e3182575f61

Zhai P., Sciarretta S., Galeotti J., Volpe M., Sadoshima J. Differential roles of GSK-3β during myocardial ischemia and ischemia/reperfusion. Circ. Res. 2011; 109(5):502-511. DOI: https://doi.org/10.1161/CIRCRESAHA.111.249532

Matsui Y., Takagi H., Qu X., Abdellatif M., Sakoda H., Asano T. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ. Res. 2007; 100(6):914-922. DOI: https://doi.org/10.1161/01.RES.0000261924.76669.36

Juhaszova M., Zorov D.B., Kim S.H., Pepe S., Fu Q., Fishbein K.W. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J. Clin. Invest. 2004; 113(11):1535-1549. DOI: https://doi.org/10.1172/JCI200419906

Fuglesteg B.N., Tiron C., Jonassen A.K., Mjøs O.D., Ytrehus K. Pretreatment with insulin before ischaemia reduces infarct size in Langendorff-perfused rat hearts. Acta Physiol. (Oxf.) 2009; 195(2):273-282. DOI: https://doi.org/10.1111/j.1748-1716.2008.01901.x

Sciarretta S., Forte M., Frati G., Sadoshima J. New insights into the role of mTOR signaling in the cardiovascular system. Circ. Res. 2018; 122(3):489-505. DOI: https://doi.org/10.1161/CIRCRESAHA.117.311147

Sanches-Silva A., Testai L., Nabavi S.F., Battino M., Pandima Devi K., Tejada S., et al. Therapeutic potential of polyphenols in cardiovascular diseases: Regulation of mTOR signaling pathway. Pharmacol. Res. 2020; 152:104626. https://doi.org/10.1016/j.phrs.2019.104626 DOI: https://doi.org/10.1016/j.phrs.2019.104626

Bishu K., Ogut O., Kushwaha S., Mohammed S.F., Ohtani T., Xu X., et al. Anti-remodeling effects of rapamycin in experimental heart failure: dose response and interaction with angiotensin receptor blockade. PLoS One. 2013; 8:e81325. DOI: https://doi.org/10.1371/journal.pone.0081325

Griffin S.J., Leaver J.K., Irving G.J. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017; 60:1620-1629. DOI: https://doi.org/10.1007/s00125-017-4337-9

K P., V M. A review of safety, quality, regulation, and delivery approaches for phytopharmaceuticals. Jordan J. Pharm. Sci. 2024 Jun. Available from: https://jjournals.ju.edu.jo/index.php/jjps/article/view/1768

Kzar H.H., Al-Gazally M.E., Wtwt M.A. Everolimus loaded NPs with FOL targeting: preparation, characterization and study of its cytotoxicity action on MCF-7 breast cancer cell lines. Jordan J. Pharm. Sci. 2022 Mar 1. Available from: https://jjournals.ju.edu.jo/index.php/jjps/article/view/286 DOI: https://doi.org/10.35516/jjps.v15i1.286

Widyananda M.H., Kurniasari C.A., Alam F.M., Rizky W.C., Dings T.G.A., Ansori A.N.M., Antonius Y. Exploration of potentially bioactive compounds from fingerroot (Boesenbergia rotunda L.) as inhibitor of atherosclerosis-related proteins (CETP, ACAT1, OSC, sPLA2): An in silico study. Jordan J. Pharm. Sci. 2023 Sep 23. Available from: https://jjournals.ju.edu.jo/index.php/jjps/article/view/1609 DOI: https://doi.org/10.35516/jjps.v16i3.1609